The Therapeutic Potential of 4-1BB (CD137) in Cancer

Author(s): Kyung-Ok Nam, Woo J. Kang, Byoung S. Kwon, Sung J. Kim, Hyeon-Woo Lee

Journal Name: Current Cancer Drug Targets

Volume 5 , Issue 5 , 2005

Become EABM
Become Reviewer


Techniques for modulating immune cells for cancer therapy have been widely studied. One key approach that is being clinically tested is developing tumor-destructive cell-mediated immune responses by regulating co-stimulatory molecules. 4-1BB (CD137), a member of the TNF receptor family, is expressed following activation of T and NK cells. Recently, it has been reported that DCs also express 4-1BB. Crosslinking of 4-1BB provides a potent co-stimulatory signal for lymphocytes via signal transduction pathways that modulate a number of cellular responses. One remarkable response is stimulation of anti-tumor activity in vivo and in vitro. We here review the potential role of 4-1BB in cancer immunotherapy focusing on the cellular and molecular mechanisms involved.

Keywords: cd t cells, cancer, signaling pathways

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [357 - 363]
Pages: 7
DOI: 10.2174/1568009054629681
Price: $65

Article Metrics

PDF: 5